Do Allergy Shots Cure Allergies? Cure vs. Remission Explained
Allergy shots do not technically cure allergies — they induce long-term clinical remission described as sustained tolerance rather than permanent eradication. About 85-90% achieve significant improvement after a 3- to 5-year course, and roughly 75% maintain that improvement years after stopping. SCIT also prevents new allergen sensitizations and reduces asthma development risk in children — the closest evidence of disease modification available.
7 peer-reviewed sources
Allergy shots produce long-term clinical remission in most patients rather than a guaranteed permanent cure. About 85-90% achieve significant symptom reduction, and disease-modifying effects can persist for years after stopping treatment.
What 'Cure' Actually Means — And Whether Allergy Shots Qualify
The word 'cure' carries a specific medical meaning: permanent eradication of a disease such that symptoms cannot return. By that strict definition, no currently available treatment for allergic disease qualifies as a cure. Allergists instead use the term 'clinical remission' — sustained absence of meaningful symptoms without ongoing treatment. SCIT is the only treatment that reliably induces this state.
Here is the honest picture: approximately 85 to 90% of patients who complete a full 3- to 5-year SCIT course achieve significant symptom reduction, often eliminating daily medication dependence. About 75% maintain that improvement for years after stopping — and some for a decade or more. The remaining 25% experience clinically significant relapse, most within 3 years of stopping treatment.
The FDA does not permit 'cure' claims on any SCIT product labeling, reflecting that immunologic tolerance — not disease eradication — is the correct technical description. However, SCIT goes further than any other allergy treatment: it can prevent the development of new allergen sensitivities in monosensitized patients, and the landmark PAT study showed that children who received SCIT had dramatically lower odds of developing asthma over the following decade.
Knowing exactly which allergens are responsible for your symptoms is the essential first step before any immunotherapy. At-home allergy testing from Curex covers 40 or more specific IgE triggers and delivers results within about a week, ensuring treatment targets the actual drivers of your allergic disease.
SCIT is the closest thing to a cure for allergic disease — it produces lasting clinical remission in most patients and may prevent new allergies and asthma from developing — but the correct clinical term is remission, not cure.
Why SCIT Produces Remission Rather Than a Permanent Cure
Understanding why SCIT does not technically cure allergies requires understanding the difference between allergen sensitization and allergic disease. Sensitization — the presence of specific IgE antibodies to an allergen — is established in early life through complex genetic and environmental interactions. SCIT cannot erase these IgE memory B cells permanently. What it does instead is add a powerful counter-regulatory layer: it induces allergen-specific regulatory T cells (Tregs), shifts antibody class from IgE to blocking IgG4, and reduces the reactivity of mast cells and basophils that drive symptoms. These changes create clinical tolerance — the allergen is still present in your blood in low levels, but the immune response to allergen exposure is suppressed. The reason relapse occurs in about 25% of patients is that this counter-regulatory machinery is not infinitely self-sustaining. IgG4 blocking antibody levels gradually decline after stopping, and in some patients the Th2-dominant allergic pathway re-emerges over months to years. In others — particularly those with single-allergen sensitization who completed full treatment — the tolerance appears genuinely self-reinforcing and persists for over a decade.
Allergen Exposure Begins
Allergen extract is injected subcutaneously, where dermal dendritic cells capture and process the allergen peptides. This sets the stage for immune retraining rather than immune attack.
Regulatory T Cells Are Induced
Dendritic cells present the allergen to naive T cells in a tolerogenic context, driving the development of FOXP3+ regulatory T cells (Tregs) that produce IL-10 and TGF-beta. These Tregs specifically suppress the allergen-driven Th2 inflammatory response.
IgG4 Blocking Antibodies Rise
B cells switch production from IgE (the antibody that triggers allergic reactions) to IgG4 (blocking antibodies). IgG4 rises 10- to 100-fold and competes with IgE for allergen binding, preventing mast cell activation that causes symptoms.
Immune Memory Established
After 3 to 5 years, the regulatory immune program is sufficiently established that it can persist independently for years after stopping. Disease modification — including prevention of new sensitizations and reduced asthma risk — represents the deepest level of this immune remodeling.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
The Strongest Evidence That SCIT Is Cure-Adjacent
Three categories of evidence make the strongest case that SCIT achieves outcomes beyond symptom management: disease modification, long-term post-treatment benefit, and asthma prevention. No other allergy treatment has produced evidence in all three categories at the clinical trial level.
Success Rate by Duration
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSCIT vs. Other Treatments: Which Gets Closest to a Cure?
No allergy treatment currently available meets the medical definition of cure. However, treatments differ dramatically in how close they get. Antihistamines, nasal steroids, and decongestants provide symptom control only while taken — they produce zero disease modification and offer nothing beyond temporary relief. SCIT is in a fundamentally different category: it is the only widely available treatment shown to produce lasting clinical remission after stopping, prevent new sensitizations, and reduce asthma development in children.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
Allergy Shots (SCIT)Best | 85-90% achieve significant improvement; disease modification documented up to 12 years post-treatment | 3-5 years active treatment | $3,000-15,000 | Weekly injections during build-up, then monthly; a 30-minute wait traditionally meant a clinic visit, but with Curex the shot is self-administered at home with a brief self-observation, first dose and dose changes supervised live over Zoom | Small systemic reaction risk; requires supervised injection setting |
Sublingual Drops (SLIT) | Comparable clinical remission to SCIT; same disease-modifying mechanism via Treg induction and IgG4 class switch | 3-5 years daily drops | $2,340-3,000 | Daily at-home drops; no injections, no clinic waits | Markedly safer than SCIT; no confirmed fatalities in published literature |
Antihistamines | Symptom control only; no disease modification; symptoms return fully when stopped | Indefinite daily use | $600-2,500 | Daily pill; widely available OTC | Sedation risk with older antihistamines; no immune modification |
- Efficacy
- 85-90% achieve significant improvement; disease modification documented up to 12 years post-treatment
- Duration
- 3-5 years active treatment
- Cost (5yr)
- $3,000-15,000
- Convenience
- Weekly injections during build-up, then monthly; a 30-minute wait traditionally meant a clinic visit, but with Curex the shot is self-administered at home with a brief self-observation, first dose and dose changes supervised live over Zoom
- Safety
- Small systemic reaction risk; requires supervised injection setting
- Efficacy
- Comparable clinical remission to SCIT; same disease-modifying mechanism via Treg induction and IgG4 class switch
- Duration
- 3-5 years daily drops
- Cost (5yr)
- $2,340-3,000
- Convenience
- Daily at-home drops; no injections, no clinic waits
- Safety
- Markedly safer than SCIT; no confirmed fatalities in published literature
- Efficacy
- Symptom control only; no disease modification; symptoms return fully when stopped
- Duration
- Indefinite daily use
- Cost (5yr)
- $600-2,500
- Convenience
- Daily pill; widely available OTC
- Safety
- Sedation risk with older antihistamines; no immune modification
Patients who want the closest thing to a cure from allergic disease — without weekly clinic injections — can get the shot itself through Curex at home for $129/month. The personalized serum is sterile-compounded to USP <797> and prescribed by a board-certified allergist; your first injection and every dose change are supervised live over Zoom, a prescribed epinephrine auto-injector is confirmed on hand, and dosing escalates gradually week by week — the same immune-retraining pathway as clinic shots, only the setting changes for eligible maintenance patients.
See if at-home shots are right for youFrequently asked questions
Do allergy shots permanently cure allergies?
Allergy shots do not permanently cure allergies in the strict medical sense — no current treatment achieves permanent eradication of the allergic disease process. What SCIT provides is long-term clinical remission: sustained, meaningful reduction in symptoms that persists for years after stopping treatment in most patients. The distinction matters because roughly 25% of patients do relapse, most within 3 years of stopping. The correct framing from allergists and the World Allergy Organization is that SCIT produces 'sustained clinical tolerance' rather than a cure, with disease-modifying effects that no other allergy treatment can match.
What percentage of allergy shot patients are effectively cured?
Approximately 30 to 40% of optimally treated patients achieve what could practically be called a cure — complete or near-complete symptom resolution that persists without ongoing treatment. A broader 85 to 90% of SCIT completers achieve significant improvement sufficient to reduce or eliminate daily medication use. The difference depends on definition: complete symptom freedom versus major improvement. Data from Durham et al. and Cox et al. suggest that 75% of patients who complete a full 3- to 5-year course maintain their gains 3 years after stopping, which is the closest measurable endpoint to durable cure available in the allergy field.
Why do allergists avoid the word 'cure' for allergy shots?
Allergists avoid the word 'cure' for two reasons: medical accuracy and regulatory compliance. Medically, cure implies permanent eradication of the disease mechanism — a state allergy shots cannot guarantee, since approximately 25% of treated patients relapse. Regulatory compliance also plays a role: the FDA does not permit cure claims on any SCIT product labeling. The preferred clinical terminology is 'sustained clinical tolerance,' 'clinical remission,' or 'disease modification' — terms that accurately reflect what SCIT delivers: a powerful, lasting reduction in allergic reactivity that often persists for years after treatment ends, without claiming guaranteed permanent elimination.
Can allergy shots prevent new allergies from developing?
Evidence from several studies suggests that SCIT can prevent new allergen sensitizations in monosensitized patients — a powerful form of disease modification beyond symptom control. Des Roches et al. (JACI 1997) found that 45% of SCIT-treated monosensitized children developed no new sensitizations compared to 0% of untreated controls. Purello-D'Ambrosio found that polysensitization developed in only 23.75% of SCIT-treated patients versus 68% of untreated patients over 4 years. While the best-quality randomized evidence remains limited, this prevention of new sensitizations represents one of the strongest arguments that SCIT achieves outcomes beyond symptom management.
Do allergy shots prevent asthma from developing?
The PAT (Preventive Allergy Treatment) study provides the strongest evidence that SCIT reduces asthma development in children with allergic rhinitis. Moller et al. (JACI 2002) randomized 205 children aged 6 to 14 with grass or birch pollen rhinitis; the SCIT group showed significantly fewer asthma symptoms during the 3-year treatment period. The 10-year follow-up by Jacobsen et al. (Allergy 2007) confirmed that 25% of treated children developed asthma compared to 45% of untreated controls — an odds ratio of approximately 2.5 to 4.6 favoring SCIT. Translating into practical terms, approximately 5 to 6 children need to be treated with SCIT to prevent one new case of asthma.
How does SCIT compare to a cure for venom allergy?
Venom immunotherapy (VIT) comes closest to a functional cure of any allergy treatment. After completing a 3- to 5-year course of VIT, 95 to 98% of treated patients are protected against future life-threatening reactions from insect stings — a level of protection described by the AAAAI as one of the most effective outcomes in all of medicine. After 5 years of VIT, most patients can discontinue treatment with maintained protection. Unlike inhalant allergy SCIT, where 25% relapse, VIT relapse rates are much lower for most patients. Patients with mastocytosis or very severe initial reactions are typically recommended indefinite VIT.
Is clinical remission from allergy shots the same as being cured?
Clinical remission means your symptoms are absent or minimal without ongoing treatment — which functionally resembles a cure for most patients. The clinical distinction is that remission can relapse, whereas a cure by definition cannot. For the 75% of SCIT completers who maintain their improvement for years without relapse, the day-to-day experience is indistinguishable from being cured. For the 25% who do relapse, retreatment is an option. The WAO and major allergy organizations use 'sustained clinical tolerance' or 'clinical remission' to be precise, while acknowledging that SCIT's disease-modifying effects represent a qualitatively different outcome than symptom management with daily medications.
Related Articles
How Long Do Allergy Shots Take? Trial vs Reality | Curex
How long do allergy shots take to work? Trials show 12-month benefit, but only 23% complete 3 years. Real-world vs clinical data guide.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT trains your immune system to tolerate allergens over 3-5 years. 85-90% of patients see significant improvement.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.